公开(公告)号：US20230052495A1

公开(公告)日：2023-02-16

申请号：US17869055

申请日：2022-07-20

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Fabio BAGNOLI ,  Carine GORAJ

IPC: A61K39/085 ,  A61P31/04

Abstract: The invention provides an immunogenic composition comprising staphylococcal antigens, containing protein antigens and conjugates of capsular polysaccharides. Adjuvanted formulations are also provided. The invention may find use in the prevention and treatment of staphylococcal infections.

公开(公告)号：US20210023192A1

公开(公告)日：2021-01-28

申请号：US16968895

申请日：2019-02-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Fabio BAGNOLI ,  Carine GORAJ

IPC: A61K39/085 ,  A61P31/04

Abstract: The invention provides an immunogenic composition comprising staphylococcal antigens, containing protein antigens and conjugates of capsular polysaccharides, n particular Hla, ClfA, SpA and conjugates of capsular polysaccharides. Adjuvanted formulations are also provided. The invention may find use in the prevention and treatment of staphylococcal infections, in particular S. aureus infection and disease.

公开(公告)号：US20180104322A1

公开(公告)日：2018-04-19

申请号：US15832240

申请日：2017-12-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Ralph Leon BIEMANS ,  Dominique BOUTRIAU ,  Philippe Thomas DENOEL ,  Pierre DUVIVIER ,  Carine GORAJ

IPC: A61K39/085 ,  A61K39/00

CPC classification number: A61K39/085 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.

公开(公告)号：US20170281744A1

公开(公告)日：2017-10-05

申请号：US15529094

申请日：2015-12-08

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Ralph Leon BIEMANS ,  Dominique BOUTRIAU ,  Philippe DENOEL ,  Pierre DUVIVIER ,  Carine GORAJ

IPC: A61K39/085 ,  A61K45/06 ,  C07K14/31

CPC classification number: A61K39/085 ,  A61K39/00 ,  A61K45/06 ,  A61K2039/555 ,  A61K2039/58 ,  A61K2039/6037 ,  A61K2039/70 ,  C07K14/31 ,  C07K2319/00

Abstract: The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the pH of the composition is pH 5.0-pH 8.0. The application further discloses an immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0